Nottingham Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Nottingham Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,979	Closed	-$30.8K	–	172
2024 Q2	$30.8K	Hold	11,979	–	–	﹤0.01%	155
2024 Q1	$58.9K	Hold	11,979	–	–	0.01%	136
2023 Q4	$105K	Hold	11,979	–	–	0.01%	129
2023 Q3	$137K	Hold	11,979	–	–	0.02%	123
2023 Q2	$303K	Sell	11,979 -200	-2%	-$6.23K	0.04%	106
2023 Q1	$392K	Sell	12,179 -1,133	-9%	-$35.3K	0.05%	102
2022 Q4	$246K	Hold	13,312	–	–	0.03%	128
2022 Q3	$359K	Hold	13,312	–	–	0.05%	99
2022 Q2	$184K	Hold	13,312	–	–	0.03%	124
2022 Q1	$260K	Hold	13,312	–	–	0.03%	121
2021 Q4	$217K	Hold	13,312	–	–	0.02%	139
2021 Q3	$371K	Hold	13,312	–	–	0.04%	104
2021 Q2	$395K	Hold	13,312	–	–	0.04%	102
2021 Q1	$372K	Hold	13,312	–	–	0.04%	110
2020 Q4	$377K	Hold	13,312	–	–	0.05%	100
2020 Q3	$335K	Hold	13,312	–	–	0.04%	104
2020 Q2	$349	Buy	13,312 +2,000	+18%	+$39.5K	0.02%	95
2020 Q1	$167K	Buy	11,312 +1,308	+13%	+$27.1K	0.03%	106
2019 Q4	$162K	Sell	10,004 -2,000	-17%	-$31K	0.02%	107
2019 Q3	$156K	Buy	12,004 +2,000	+20%	+$24.5K	0.02%	106
2019 Q2	$130K	Hold	10,004	–	–	0.02%	109
2019 Q1	$158K	Sell	10,004 -1,308	-12%	-$22.7K	0.02%	104
2018 Q4	$281K	Hold	11,312	–	–	0.04%	88
2018 Q3	$281K	Hold	11,312	–	–	0.04%	85
2018 Q2	$348K	Hold	11,312	–	–	0.05%	71
2018 Q1	$348K	Hold	11,312	–	–	0.06%	63
2017 Q4	$404K	Hold	11,312	–	–	0.06%	78
2017 Q3	$312K	Sell	11,312 -2,000	-15%	-$48.5K	0.04%	86
2017 Q2	$351K	Hold	13,312	–	–	0.05%	83
2017 Q1	$277K	Hold	13,312	–	–	0.04%	90
2016 Q4	$276K	Hold	13,312	–	–	0.05%	93
2016 Q3	$216K	Sell	13,312 -3,000	-18%	-$43.6K	0.04%	105
2016 Q2	$222K	Sell	16,312 -2,016	-11%	-$35.6K	0.04%	80
2016 Q1	$626K	Hold	18,328	–	–	0.12%	57
2015 Q4	$626K	Hold	18,328	–	–	0.12%	57
2015 Q3	$545K	Hold	18,328	–	–	0.1%	62
2015 Q2	$586K	Sell	18,328 -436	-2%	-$11.2K	0.1%	67
2015 Q1	$389K	Sell	18,764 -4,254	-18%	-$73.5K	0.06%	72
2014 Q4	$390K	Buy	+23,018	New	+$402K	0.1%	65

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Nottingham Advisors's RVNC Position: Q3 2024 in Review

Nottingham Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 11,979 shares — an estimated $30.8K sold.

Nottingham Advisors first reported a position in RVNC in Q4 2014 and held it in 39 quarters. The position peaked at $626K in Q1 2016. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

Nottingham Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
Nottingham Advisors sold 11,979 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $30.8K.
Nottingham Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 39 quarters.
Nottingham Advisors's Revance Therapeutics, Inc. position peaked at $626K in Q1 2016.
201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Nottingham Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.